Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.3K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

477
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
477
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

920
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

882
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. Carmelinaでは,高心血管および腎臓リスクの2型糖尿病患者における心臓機能不全および関連するアウトカムに対するリナグリプトンの効果

CARMELINAでは,高心血管および腎臓リスクの2型糖尿病患者における心臓機能不全および関連するアウトカムに対するリナグリプトンの効果

Darren K McGuire1, John H Alexander2, Odd Erik Johansen3

  • 1University of Texas Southwestern Medical Center, Dallas (D.K.M., R.D.T.).

Circulation
|December 28, 2018

関連する実験動画

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.5K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

643
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.0K

PubMed で要約を見る

まとめ
この要約は機械生成です。

2型糖尿病および心血管疾患または腎臓疾患の患者では,リンアグリプチンは心不全 (HF) のために入院を増加させなかった. CARMELINA試験のこの発見は,リナグリプチンの使用によるHFリスクに関して安心を与えます.

科学分野:

  • 心臓病科
  • 内分泌学
  • 腎臓科

背景:

キーワード:
心血管疾患慢性腎臓疾患心不全2型糖尿病

関連する実験動画

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.5K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

643
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.0K
  • 2型糖尿病 (T2DM) は,特に動脈硬化性心血管疾患 (ASCVD) や腎臓疾患の共存で,心不全 (HF) のリスクを大幅に増加させる.
  • 特定のディペプチジルペプチダース-4 (DPP-4) 阻害剤は,HFのリスクに関する懸念を提起しています.
  • リナグリプチンは,T2DM管理に使用されるDPP-4阻害剤です.

研究 の 目的:

  • T2DMおよびASCVDおよび/ または腎臓疾患の患者におけるHFおよび関連アウトカムに対するリナグリプトンの効果とプラセボの効果を評価する.
  • CARMELINA試験におけるHF入院 (hHF) と心血管のアウトカムに関する二次分析を行う.

主な方法:

  • T2DMおよびASCVDおよび/または腎臓疾患の6979人の参加者を対象としたランダム化,ダブルブラインド,プラセボ対照試験 (CARMELINA).
  • 参加者は,通常の治療に加えて,毎日口服用リナグリプトン5 mgまたはプラセボを投与された.
  • HF入院,心血管疾患,死亡は前向きに記録され,中央で判断された.分析はコックス比例リスクと負の二項モデルを使用した.

主要な成果:

  • リンアグリプチンは,プラセボと比較してhHFの発生率 (HR,0. 90; 95% CI,0. 74-1. 08) に有意な影響を及ぼさなかった.
  • 心血管死亡/ hHF (HR,0. 94; 95% CI,0. 82-1. 08) の複合では有意な差異は見られなかった.
  • 繰り返し発生するhHFのリスクもグループによって類似していた (率比,0. 94; 95% CI,0. 75- 1. 20).

結論:

  • T2DMおよびASCVDおよび/ または腎疾患の患者では,リナグリプチンはHF入院のリスクを増加させなかった.
  • リナグリプチンのHFリスクへの影響は,HFの既往歴,変異性腎機能,またはベースラインの左心室排出分数を有する患者を含むサブグループで一貫していました.